Ob/Gyn Articles

Ob/Gyn

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Duchateau PX et al. – Despite the notion that oxytocin antagonist atosiban has limited or no systemic adverse effects, these results suggest that this cost–consuming drug does not avoid hypotension and cannot help to reduce the level of monitoring.

Related Articles

Neonatal outcomes associated with planned vaginal versus planned primary cesarean delivery
Journal of Perinatology, 10/09/09    Relevance Score: 88%

Medtronic Launches Global Clinical Trial Evaluating Outcomes From Comprehensive Attain Family of Left-Heart Leads and Delivery Catheters
Medtronic, 11/11/09    Relevance Score: 87%

Insurance-Based Discrimination During Prenatal Care, Labor, and Delivery: Perceptions of Oregon Mothers
Maternal and Child Health Journal, 11/04/09    Relevance Score: 87%

Failed Operative Vaginal Delivery
Obstetrics and Gynecology, 10/27/09    Relevance Score: 87%

Comparison of Gene Delivery Techniques for Therapeutic Angiogenesis
JACC - Journal of the American College of Cardiology, 10/23/09    Relevance Score: 87%

Today in Clinical Pharmacology...keeping you current

An alternative monitoring protocol for single-dose methotrexate therapy in ectopic pregnancy
American Journal of Obstetrics and Gynecology, 12/08/09

Emerging role of pemetrexed in ovarian cancer
Expert Review of Anticancer Therapy, 12/07/09

Correlates of use of antifracture therapy in older women with low bone mineral density
Journal of General Internal Medicine, 12/07/09


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Send this Summary to a Colleague

Enter email address